Theriva Biologics (NYSEAMERICAN:TOVX) Issues Quarterly Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) posted its quarterly earnings data on Tuesday. The company reported ($6.81) EPS for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56), Zacks reports.

Theriva Biologics Stock Down 1.7 %

Shares of Theriva Biologics stock traded down $0.03 during midday trading on Wednesday, reaching $1.41. 158,027 shares of the company’s stock traded hands, compared to its average volume of 1,006,092. The company has a market cap of $3.19 million, a PE ratio of -0.04 and a beta of 1.34. Theriva Biologics has a 12 month low of $1.24 and a 12 month high of $17.11.

Analyst Ratings Changes

Separately, Maxim Group dropped their price target on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.